All National Institute for Health and Care Excellence (NICE) articles
-
Industry newsNICE and EMA say new Alzheimer’s drug is ‘not recommended’
The new draft guidance from NICE states that Lecanemab is ‘not recommended’ and the EMA has recommended the refusal of the marketing authorisation for Leqembi.
-
Industry newsPatient groups get pharma funding; often petition NICE
An investigation by The Observer reveals how patient groups receiving funding from pharma often petition NICE for NHS approvals.
-
Industry newsNICE recommends its first-ever oral migraine treatment
Rimegapant – has been approved for use in the NHS giving a treatment option for people who have failed with different drug options.
-
Industry newsMHRA plans medical device technologies streamlined pathway
UK agency aims to make route-to-market much more straightforward for manufacturers with Innovative Devices Access Pathway.